Drug Screening Using Novel IMD in Renal Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2026

Conditions
Renal Cell CarcinomaMetastatic Renal Cell CarcinomaKidney Cancer
Interventions
COMBINATION_PRODUCT

Implantable Microdevice (IMD)

"Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib."

Trial Locations (1)

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Wenxin Xu

OTHER